Clinical Trial Update: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update evaluating MCLA-129, a bispecific anti-EGFR and anti-c-MET antibody, in advanced non-small cell lung cancer and other solid tumors, both …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Esophageal Squamous Cell Carcinoma
• Gastric Cancer
• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• MCLA-129

Snippet

Sponsor: Merus B.V. | Conditions: Non-Small Cell Lung Cancer Metastatic, Gastric Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING